ad image

Company Info

Coriolis Pharma

Coriolis Pharma

CDMO / Preclinical CRO

Overview

Coriolis Pharma is a globally operating and science driven contract research and development organization (CRDO). We support drug product development of biopharmaceuticals, including gene and cell therapies and vaccines, from early development to commercialization. Our focus lies on formulation development, lyophilization technologies and analytics (GMP and non-GMP) for a wide range of products.

As a privately held and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our clients.

We offer a large selection of services for all types of biopharmaceuticals, including proteins, peptides, peptides, nucleic acids, gene- and cell therapy products, vaccines and virus(-like) particles up to biosafety level S2.

Coriolis Pharma
Contributions
9 Contributions1 / 1
Advancing Subvisible Particle Characterization with Artificial Intelligence
Particle Analysis

Advancing Subvisible Particle Characterization with Artificial Intelligence

Daniel Weinbuch, Ph.D.

Coriolis Pharma

PAO-03-25-CL-02Mar 11, 2025
Ensuring Biologic Stability with Tailored and Cutting-Edge Lyophilization Solutions
Lyophilization

Ensuring Biologic Stability with Tailored and Cutting-Edge Lyophilization Solutions

Brecht Vanbillemont, Dr.; Lisa Besslich, Dr. Rer. Nat.

Coriolis Pharma

PAO-02-25-CL-12Feb 18, 2025
Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments
Developability

Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments

Andrea Arsiccio, Ph.D.,; Eva Keilhauer, Ph.D.; Kristian Le Vay, Ph.D.

Coriolis Pharma

PAO-01-25-CL-12Jan 27, 2025
Leveraging Formulation Development Experience for Effective Particle Identification
Particle ID

Leveraging Formulation Development Experience for Effective Particle Identification

Jörg Müller, Ph.D.

Coriolis Pharma

PAO-10-24-CL-10Nov 18, 2024
Development Strategies for Overcoming Commercialization Challenges
Commercialization

Development Strategies for Overcoming Commercialization Challenges

Matthias Lucke, Ph.D.

Coriolis Pharma

PAO-09-24-CL-10Sep 17, 2024
IND Enablement and Drug Product Development – Mitigating Risk and Accelerating through the "Valley of Death"
IND Enablement

IND Enablement and Drug Product Development – Mitigating Risk and Accelerating through the "Valley of Death"

Johannes Clemens

Coriolis Pharma

PAO-08-24-CL-07Aug 16, 2024
Streamlining the Path to Approval with Developability and Pre-Formulation Platforms
Developability

Streamlining the Path to Approval with Developability and Pre-Formulation Platforms

Andrea Hawe

Coriolis Pharma

PAO-07-24-CL-11Aug 01, 2024
Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development
CRDO

Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development

Silvia Steyrer-Gruber

Coriolis Pharma

PAO-07-24-CL-05Jul 16, 2024
Coriolis Pharma
Monoclonal Antibodies

Coriolis Pharma Launches U.S. Entity Alongside Innovative Drug Product Platform Service Offerings for Monoclonal Antibodies

Coriolis Pharma

PR-05-24-NI-02Jun 18, 2024
1 / 1